Patient Derived Xenograft Models Market Scope And Analysis

  • Report Code : TIPRE00021693
  • Category : Life Sciences
  • No. of Pages : 150
Buy Now

Patient-Derived Xenograft Model Market Analysis by 2031

Buy Now

Patient-Derived Xenograft Model Market Report Patient-Derived Xenograft Model Market Size and Share Patient-Derived Xenograft Model Market Scope and Analysis

Patient-Derived Xenograft Model Market Report Scope

Report Attribute Details
Market size in 2024 US$ 468.75 Million
Market Size by 2031 US$ 1,116.73 Million
Global CAGR (2025 - 2031) 13.4%
Historical Data 2021-2023
Forecast period 2025-2031
Segments Covered By Model Type
  • Mice Models and Rats Models
By Tumor Type
  • Gastrointestinal Tumor Models
  • Gynecological Tumor Models
  • Respiratory Tumor Models
  • Other Tumor Models
By Application
  • Preclinical Drug Development
  • Biomarker Analysis
  • Translational Research
  • Biobanking
By End User
  • Pharmaceutical and Biotechnology Companies
  • Contract Research Organizations
  • Academic and Government Research Institutions
Regions and Countries Covered North America
  • US
  • Canada
  • Mexico
Europe
  • UK
  • Germany
  • France
  • Russia
  • Italy
  • Rest of Europe
Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific
South and Central America
  • Brazil
  • Argentina
  • Rest of South and Central America
Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa
Market leaders and key company profiles
  • Champions Oncology Inc
  • Charles River Laboratories Inc
  • Crown Bioscience Inc
  • EPO Berlin Buch GmbH
  • Hera BioLabs
  • Horizon Discovery Group plc
  • Oncodesign
  • Pharmatest Services Ltd
  • Xentech SAS
  • JSR Corporation